Inflammatory Bowel Disease
Filter News
Found 71 articles
-
The private placement from existing and new investors extends the company’s cash runway into the second half of 2026 and will help take two candidates for inflammatory bowel disease into the clinic in 2024.
-
Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease
12/5/2023
Geneoscopy, Inc. and Adiso Therapeutics, Inc. today announced a strategic collaboration to further treatment options available for patients with inflammatory bowel disease (IBD).
-
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
11/24/2023
Sosei Group Corporation announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases.
-
After a negative review by an Independent Data Monitoring Committee, InDex Pharmaceuticals has decided to discontinue the late-stage CONCLUDE program evaluating its cobitolimod in ulcerative colitis.
-
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
11/9/2023
ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.
-
Novel Immune Modulator Has Potential to Change Treatment Approach in Rheumatoid Arthritis and Ulc...
11/3/2023
A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC). -
The regulator has approved the first-ever subcutaneous version of infliximab, an IgG1 monoclonal antibody, commonly sold by Johnson & Johnson under the brand name Remicade.
-
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease
10/23/2023
Celltrion USA announced that the U.S. Food and Drug Administration has approved ZYMFENTRA® for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease following treatment with an infliximab product administered intravenously.
-
In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.
-
The regulator's approval of oral, once-daily etrasimod, to be marketed as Velsipity, was based on favorable Phase III safety and efficacy data showing significant clinical remission of ulcerative colitis.
-
Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting
10/5/2023
Geneoscopy Inc. will present at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, Canada, Oct. 20-25, highlighting how its novel platform technology is being used to develop noninvasive diagnostic and precision medicine tools for gastrointestinal (GI) diseases, such as colorectal cancer (CRC) and inflammatory bowel disease (IBD).
-
The French pharma paid $500 million upfront, with up to $1 billion in future milestone payments, to co-develop and co-commercialize Teva’s Phase II anti-TL1A antibody for inflammatory bowel disease.
-
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
10/4/2023
Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announce a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
-
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
10/4/2023
Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announce a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
-
Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
9/12/2023
Takeda Canada Inc. is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge, a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences.
-
Healing the Wounds of Inflammatory Bowel Disease
8/30/2023
The state-of-the-art isn't enough when it comes to treating Crohn's disease and ulcerative colitis, the two major types of inflammatory bowel diseases.
-
Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease
8/15/2023
Research has shown that a novel antibody generated to target an 'essential amino acid sequence' of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).
-
Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease
8/3/2023
Celsius Therapeutics today announced the initiation of dosing in the company’s first-in-human Phase 1 clinical trial of CEL383 in healthy volunteers.
-
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
7/27/2023
Telavant, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to help patients living with inflammatory and fibrotic diseases, announced today the initiation of the TAHOE study, a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active CD, with first patient dosed.
-
Microba Commences Phase I Clinical Trial for IBD Therapeutic
6/28/2023
Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.